The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer

Breast Journal

Volumn 13, Issue 6, 2007, Pages 581-587

  Richardson, Lisa C ^a   Wang, Wei ^b   Hartzema, Abraham G ^c   Wagner, Samuel ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d PFIZER INC   (United States)

Author keywords

Breast cancer; Quality of life; Treatment adherence

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAIR LOSS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUROTOXICITY; PSYCHOPATHY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMATITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT DROPOUTS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; VINCRISTINE;

EID: 35748959324     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00512.x     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2000 56 : 106 30.
2. Ganz PA, Moinpour CM, Cella DF, Fetting JH. Quality-of-life assessment in cancer clinical trials: a status report. J Natl Cancer Inst 1992 84 : 994 5.
3. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 2004 96 : 376 87.
4. Gotay CC. Assessing cancer-related quality of life across a spectrum of applications. J Natl Cancer Inst Monographs 2004 33 : 126 33.
5. Moinpour CM, Feigl P, Metch B, et al. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989 81 : 485 95.
6. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM. Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 1999 8 : 723 31.
7. Hurny C, Bernhard J, Coates AS, et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 1996 347 : 1279 84.
8. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001 19 : 322 8.
9. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 351 : 1451 67.
10. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998 352 : 930 42.
11. Fetting JH, Gray R, Fairclough DL, et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol 1998 16 : 2382 91.
12. Levine MN, Guyatt GH, Gent M, et al. Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 1988 6 : 1798 810.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 5 : 649 55.
14. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996 88 : 1529 42.
15. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003 21 : 602 6.
16. Ayres A, Hoon PW, Franzoni JB, et al. Influence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer patients. J Psychosom Res 1994 38 : 393 402.
17. Gilbar O, De Nour AK. Adjustment to illness and dropout of chemotherapy. J Psychosom Res 1989 33 : 1 5.
18. Nerenz DR, Leventhal H, Love RR. Factors contributing to emotional distress during cancer chemotherapy. Cancer 1982 50 : 1020 7.
19. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988 6 : 1746 52.
20. Wenzel LB, Fairclough DL, Brady MJ, et al. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 1999 86 : 1768 74.
21. Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 2000 18 : 3125 34.
22. Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer 1989 63 : 604 12.
23. Cassileth BR, Lusk EJ, Strouse TB, Bodenheimer BJ. Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med 1984 101 : 105 12.
24. Kissane DW, Clarke DM, Ikin J, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey [see comment]. Med J Aust 1998 169 : 192 6.
25. Rosman S. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 2004 52 : 333 9.
26. Verhoef MJ, White MA. Factors in making the decision to forgo conventional cancer treatment. Cancer Pract 2002 10 : 201 7.
27. Williams J, Wood C, Cunningham-Warburton P. A narrative study of chemotherapy-induced alopecia. Oncol Nurs Forum 1999 26 : 1463 8.
28. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001 9 : 283 9.
29. Khoo KS, Ang PT, Lim AG. Common toxicities of cancer chemotherapy. Sing Med J 1993 34 : 418 20.
30. Tierney AJ, Taylor J, Closs SJ. Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer. Scan J Car Sci 1992 6 : 75 80.
31. Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997 76 : 1055 61.
32. Hershman DL, McBride RB, Jacobson JS, et al. Treatment duration and survival in women of African ancestry undergoing chemotherapy for early-stage breast cancer. Breast Cancer Res Treat 2005 84 (Suppl. 1 S96.
33. Chang CH, Cella D, Masters GA, et al. Real-time clinical application of quality-of-life assessment in advanced lung cancer. Clin Lung Cancer 2002 4 : 104 9.